Actr T Cell Product
HER-2 Protein Overexpression
Cogent Biosciences, Inc.Cell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the HER-2 Protein Overexpression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB NKGen Biotech, Inc. | Phase 2 | BB |
Zanidatamab Jazz Pharmaceuticals | Phase 2 | B |
Pyrotinib Tianjin Medical University Second Hospital | Phase 2 | CCC |
her2 dc1 vaccine H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | CCC |
Irinotecan Jin-Hee Ahn | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
Actr T Cell Product is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →